CD160 Expression in Corneal Vessels
- Conditions
- LymphangiogenesisAngiogenesisCorneal Graft RejectionCD160
- Registration Number
- NCT05009407
- Lead Sponsor
- CHU de Reims
- Brief Summary
Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis
- Detailed Description
After informed consent, patients enrolled for corneal graft surgery at the Robert Debré University Hospital, Reims, France, will be included.
Routine general and eye examination including cornea photographs will be performed.
During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared for immunohistochemistry analyzes.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 20
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Micro-vascular densities 1 year neovascularization scores quantification of blood (anti-ERG+/anti-D2-40-) and lymphatic (anti-ERG+/anti-D2-40+) vascular structures ; Percentages of those vascular structures marked with anti-CD160
- Secondary Outcome Measures
Name Time Method Percentages of those vascular structures marked with anti-CD160 and/or CD105 and/or aSMA 1 year Evaluation of clinical blood vascular densities on photographs with help of ImageJ software 1 year
Trial Locations
- Locations (1)
Damien JOLLY
🇫🇷Reims, France
Damien JOLLY🇫🇷Reims, FranceAlexandre DENOYERContact03 26 78 78 88adenoyer@chu-reims.fr